drugset / Trial / NCT02368587
Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy
Phase 2
Unknown
160 enrolled
Navy General Hospital, Beijing
First People's Hospital of Foshan · collabGeneral Hospital of Armed Police, Beijing · collabPLA General Hospital, Beijing · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate the safety and efficacy of intracoronary or intravenous infusion human umbilical Wharton's jelly-derived Mesenchymal Stem Cell (WJMSC) in patients with ischemic cardiomyopathy secondary to myocardial infarction.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2021-01-01
- Completion
- 2021-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | WJMSCs | Cell therapy | — | Intrathecal |